All In Biotech

Drug Trial Radar · NCT06754891

Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

A Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 in Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

Jul 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and Pharmacokinetics/Pharmacodynamics (PK/PD) characteristics of TQH3906 capsules in subjects with moderate-to-severe active ulcerative colitis. The study will include a maximum 4-week screening period, a 12-week treatment period, and a 4-week post-treatment follow-up period, enrolling a total of 105 subjects. Among these, subjects who failed conventional therapy and those who failed biologic therapy each constitute 35% of the cohort. week treatment period, and a 4-week post-treatment follow-up period. A total of 105 subjects will be enrolled, with 50% comprising subjects who failed conventional therapy and 50% comprising subjects who failed biologic therapy. Dose Group Design: Group A: Placebo Group B: 32mg dose group Group C: 24mg bid dose group The specific dose will be determined based on the 48mg dose group's medication experience from Phase I and adjusted as necessary.

Conditions

  • Inflammatory Bowel Diseases

Interventions

  • 24mg bid TQH3906 capsuleDrug

    TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.

  • 32mg TQH3906 capsuleDrug

    TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.

  • TQH3906 placeboDrug

    TQH3906 is an allosteric inhibitor targeting kinase developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse event rateTime frame: Baseline up to week 16
  2. Clinical remission rate: Ulcerative colitis (UC): Mayo scoreTime frame: Week 8
  3. Clinical remission rate: Ulcerative colitis (UC): Crohn's disease (CD)Time frame: Week 8

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affilliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Not yet recruiting

  • First affiliated hospital of guangzhou medical university

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhujiang Hospital, of Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Huizhou First People's Hospital

    Huizhou, Guangdong, China · Not yet recruiting

  • Heilongjiang provincial hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital)

    Luoyang, Henan, China · Not yet recruiting

  • Luoyang First People's Hospital

    Luoyang, Henan, China · Not yet recruiting

  • Nanyang Second General Hospital

    Nanyang, Henan, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy

    Wuhan, Hubei, China · Not yet recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The First Affiliated Hospital Of University Of South China

    Hengyang, Hunan, China · Not yet recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Meihekou Central Hospital

    Meihekou, Jilin, China · Not yet recruiting

  • Shengjing Hospital oh China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The Second School of Clinical Medicine of Shandong First Medical University

    Taishan, Shandong, China · Not yet recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The TCM Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Recruiting

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Not yet recruiting

  • Taizhou Municipal Hospital

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.